Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 11, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.m.
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 3, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 1, 2019 , the Compensation Committee of Sage’s Board of
View HTML
Toggle Summary Sage Therapeutics to Host “Sage FutureCast” Webcast
Event will provide an R&D and portfolio review across the depression, neurology and neuropsychiatric franchises CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system
View HTML
Toggle Summary Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare
View HTML
Toggle Summary Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection
On track for full commercial launch in the U.S. in late June CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 14, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S.
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019 , the Compensation Committee of Sage’s Board of
View HTML
Toggle Summary Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 40 th Annual Global Healthcare
View HTML
Toggle Summary Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass --(BUSINESS WIRE)--May 14, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare
View HTML
Toggle Summary Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019 , the Compensation Committee of Sage’s Board of
View HTML